Ng Carey 4

What Happened

• Ng Carey, a director of Immix Biopharma (IMMX), received equity awards reported on Form 4 for transactions dated 2026-05-22.
• The filing shows two grants: 6,250 restricted stock units (RSUs) granted at $0.00 and a 12,500-share derivative award (a stock option) also reported at $0.00. The grants have no cash purchase price at grant; the filing does not disclose any option strike price or immediate cash value.

Key Details

• Transaction date: 2026-05-22. Form 4 filed: 2026-05-29.
• Awards: 6,250 RSUs (vest in full on earlier of the one-year anniversary or the issuer’s 2027 annual meeting, subject to continued service); 12,500-share stock option (vests in substantially equal monthly installments over the 12 months after grant, or any remaining portion at the 2027 annual meeting, subject to continued service). (Footnotes F1, F3)
• Reported acquisition price: $0.00 for both awards (grant value not stated on Form 4; option strike not disclosed).
• Shares owned after the transaction: not specified in the provided filing details.
• Reporting relationship: Ng Carey is also Managing Director of Mesa Verde Venture Partners III, LP and disclaims beneficial ownership of securities held by that entity except to the extent of any pecuniary interest. (Footnote F2)
• Filing timing: the report was filed seven days after the transaction date (5/22 → 5/29); typical Form 4 deadline is within 2 business days of the transaction, so this gap is notable.

Context

• These are grant/award transactions (code A), not open-market purchases or sales — they reflect compensation/equity incentives rather than immediate insider buying or selling.
• RSUs and restricted option awards often vest over time and are contingent on continued service; they do not necessarily indicate near-term selling or buying by the insider.
• For retail investors, awards to directors are common as compensation/retention tools; they are informative about alignment but not a direct market transaction indicating conviction.